Business Description
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Business History
Price Overview
Last updated: Jun 27, 2026 10:03am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 0.95
Total Equity: $647.81M
Shares: 119,987,000
Total Debt: $5.02M
Cash: $120.50M
EBITDA: $68.35M
Total Debt: $5.02M
Cash: $120.50M
Revenue: $761.41M
Revenue: $761.41M
Revenue: $761.41M
Total Equity: $647.81M
Tax Rate: -49.9%
Equity: $647.81M
Total Debt: $5.02M
Cash: $120.50M
Current Liabilities: $166.09M
Long-Term Debt: $5.02M
Total Debt: $5.02M
Total Equity: $647.81M
Shares: 119,987,000
Shares: 119,987,000
CapEx: -$211,000
Shares: 119,987,000
Stock Price: $87.32
Net Income: $99.65M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 21, 2026 7:15pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $366.0M | $401.9M | $482.4M | $675.0M | $761.4M |
| Cost of Revenue | $5.3M | $5.4M | $6.5M | $10.9M | $13.0M |
| Gross Profit | $360.7M | $396.5M | $475.9M | $664.2M | $748.4M |
| Operating Expenses | $236.2M | $283.8M | $368.6M | $527.2M | $703.6M |
| Operating Income | $124.5M | $112.6M | $107.3M | $137.0M | $44.8M |
| Net Income | $112.5M | $101.4M | $106.1M | $139.7M | $99.7M |
| EBITDA | $128.0M | $117.5M | $125.6M | $162.8M | $68.4M |
| EPS | $0.97 | $0.95 | $1.02 | $1.35 | $0.95 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:15pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $77.6M | $66.3M | $135.6M | $127.7M | $120.5M |
| Total Current Assets | $266.5M | $499.3M | $458.6M | $471.6M | $485.5M |
| Total Assets | $423.8M | $583.4M | $621.5M | $840.6M | $836.7M |
| Current Liabilities | $47.5M | $72.5M | $104.5M | $140.8M | $166.1M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $5.0M |
| Total Liabilities | $48.0M | $81.6M | $114.8M | $161.0M | $188.8M |
| Total Equity | $375.8M | $501.8M | $506.7M | $679.6M | $647.8M |
| Retained Earnings | $195.0M | $296.4M | $402.5M | $543.7M | $643.4M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:15pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $167.9M | $120.3M | $127.0M | $198.1M | $142.0M |
| Capital Expenditure | $-469,000 | $-413,000 | $-139,000 | -$2.2M | $-211,000 |
| Free Cash Flow | $167.4M | $119.9M | $126.9M | $195.9M | $141.8M |
| Acquisitions (net) | -$136.6M | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$296.0M | $0 | -$145.4M | -$15.7M | -$245.9M |
| Net Change in Cash | $1.4M | -$11.3M | $69.2M | -$7.9M | -$7.2M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 10:03am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$1.4B $1.2B – $1.8B
|
$1.9B $1.8B – $2.0B
|
$2.6B $2.3B – $3.1B
|
$3.1B $2.7B – $3.8B
|
| EBITDA |
$337.4M $287.2M – $435.4M
|
$472.0M $452.1M – $491.8M
|
$645.5M $558.5M – $774.5M
|
$772.7M $668.6M – $927.1M
|
| Net Income |
$368.6M $49.7M – $743.3M
|
$594.1M $378.6M – $809.7M
|
$1.1B $936.2M – $1.4B
|
$1.5B $1.2B – $1.9B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:15pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +9.8% | +20.0% | +39.9% | +12.8% |
| Gross Profit Growth | +9.9% | +20.0% | +39.6% | +12.7% |
| Operating Income Growth | -9.5% | -4.8% | +27.7% | -67.3% |
| Net Income Growth | -9.9% | +4.7% | +31.6% | -28.7% |
| EBITDA Growth | -8.2% | +6.9% | +29.6% | -58.0% |
Insider Trading (Recent)
All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-16 | WILSON JAMES N | S-Sale | 4,177.00 | $82.69 | $345,416 |
| 2026-06-16 | WILSON JAMES N | S-Sale | 5,823.00 | $83.57 | $486,633 |
| 2026-06-17 | MAHONEY DAVID L | S-Sale | 20,000.00 | $84.53 | $1.7M |
| 2026-06-15 | Mokari Atabak | M-Exempt | 40,000.00 | $19.26 | $770,400 |
| 2026-06-15 | Mokari Atabak | S-Sale | 9,434.00 | $80.02 | $754,924 |
| 2026-06-15 | Mokari Atabak | S-Sale | 11,081.00 | $80.94 | $896,923 |
| 2026-06-15 | Mokari Atabak | M-Exempt | 40,000.00 | $19.26 | $770,400 |
| 2026-06-15 | Mokari Atabak | S-Sale | 19,483.00 | $81.81 | $1.6M |
| 2026-06-15 | Mokari Atabak | S-Sale | 2.00 | $82.45 | $165 |
| 2026-06-02 | Guyer William | M-Exempt | 20,000.00 | $21.65 | $433,000 |
| 2026-06-02 | Guyer William | M-Exempt | 20,000.00 | $21.65 | $433,000 |
| 2026-06-02 | Guyer William | S-Sale | 20,000.00 | $70.60 | $1.4M |
| 2026-06-01 | Lyon Joseph Douglas | A-Award | 537.00 | $0.00 | $0 |
| 2026-06-02 | Lyon Joseph Douglas | F-InKind | 269.00 | $70.44 | $18,948 |
| 2026-06-01 | Lyon Joseph Douglas | A-Award | 537.00 | $70.44 | $37,826 |
| 2026-06-01 | Guyer William | A-Award | 877.00 | $0.00 | $0 |
| 2026-06-01 | Guyer William | A-Award | 877.00 | $70.44 | $61,776 |
| 2026-06-01 | Maduck Sean | M-Exempt | 25,000.00 | $8.27 | $206,750 |
| 2026-06-01 | Maduck Sean | M-Exempt | 25,000.00 | $8.27 | $206,750 |
| 2026-06-01 | Maduck Sean | S-Sale | 21,069.00 | $70.11 | $1.5M |
Narrative Economics
market-narrative step).